Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ISIS-GCGRRx- Dose Level 1, ISIS 449884
ISIS-GCGRRx · 3 trials · 2 indications
Change from Baseline
Change from Baseline
Change from Baseline
Change from Baseline to Week 14
| Arm | Type | Description |
|---|---|---|
| ISIS-GCGRRx | EXPERIMENTAL | ISIS-GCGRRx once weekly dosing for 13 weeks |
| Placebo | PLACEBO_COMPARATOR | once weekly dosing for 13 weeks |
| ISIS-GCGRRx - Dose Level 1 | EXPERIMENTAL | ISIS-GCGRRx - Dose Level 1 |
| ISIS-GCGRRx - Dose Level 2 | EXPERIMENTAL | ISIS-GCGRRx - Dose Level 2 |
| ISIS-GCGRRx Dose Level 1 | EXPERIMENTAL | ISIS-GCGRRx Dose Level 1 |
| ISIS-GCGRRx Dose Level 2 | EXPERIMENTAL | ISIS-GCGRRx Dose Level 2 |
| Name | Type | Description |
|---|---|---|
| ISIS-GCGRRx | DRUG | once weekly dosing for 13 weeks |
| Placebo | DRUG | once weekly dosing for 13 weeks |
| ISIS-GCGRRx- Dose Level 1 | DRUG | once weekly dosing for 26 weeks |
| ISIS-GCGRRx- Dose Level 2 | DRUG | once weekly dosing for 26 weeks |
| ISIS-GCGRRx - Dose Level 1 | DRUG | 3 doses on alternate days during the first week and then once weekly for 12 weeks |
| ISIS-GCGRRx - Dose Level 2 | DRUG | 3 doses on alternate days during the first week and then once weekly for 12 weeks |
Inclusion Criteria: * Male or female, age 18 to 75 * BMI ≥ 25.0 kg/m2 \< 36.0 kg/m2 * HbA1c ≥ 7.5% and ≤ 10.5% * Type 2 Diabetes Mellitus and on stable dose of Metformin. Patients must have been on a stable dose of oral metformin (at least 1000 mg/day) for a minimum of 3 months prior to screening e...
Top 16 of 30 competitors
ISIS-GCGRRx is an investigational drug being developed for the treatment of Type 2 Diabetes and Type 2 Diabetes Mellitus. It has been studied in Phase 2 clinical trials to evaluate its safety, tolerability, and efficacy in patients with these conditions.
ISIS-GCGRRx is being developed by Ionis Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker symbol IONS. Ionis is a biopharmaceutical company focused on discovering and developing RNA-targeted therapeutics.
ISIS-GCGRRx is in Phase 2 clinical development. It has completed two Phase 2 trials, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA for any indication.
ISIS-GCGRRx has been evaluated in completed Phase 2 trials, including NCT02824003, which studied its effect on hepatic lipid and glycogen content in Type 2 Diabetes, and NCT02583919, which assessed its safety, tolerability, and efficacy in patients with Type 2 Diabetes.
ISIS-GCGRRx - Dose Level 1 is an alternative name for ISIS-GCGRRx, referring to a specific dose level used in clinical trials. Both names refer to the same investigational drug candidate being developed by Ionis Pharmaceuticals for Type 2 Diabetes.